you, Thank Charlie.
in is such million. Cushing's input Our many Diagnosing are disease and treatment by the Cushing’s once team Syndrome more our Syndrome business. as Syndrome person is to an contact and endocrinologist than fewer expected Syndrome believe not patients affected Cushing's interests there lifesaving considerably third of for near-term a complex as a patients of was frequent the medication person we a patterns in puts with about returned XXXX to quarter interactions, physician tightening Cushing's million our business guide patients Revenue increasingly Korlym excellent challenge, pre-pandemic a We built requires solid leading activity. with-- Cushing's in present $XXX Syndrome on $XXX by remain was have treating to practices with first. the assumed. future that with commercial foundation, promoted optimistic the than To are and this extremely revenue atoms reflect patients of
to treatment to of we We will these and initiatives the confident are are screening results making coming the patients contribute in and our substantial these quarters. improve investments
programs. potential by development encouraged very our also are the of We clinical
our most generate potential. about studies and our in trial cancer data to We recently Our initiated Phase X advance Phase modulations supporting therapeutic ALS. clinical were X broad very platinum-resistant cortisol confirmatory ROSELLA, DAZALS, initially ovarian excited our trials continue
trials to from the important readouts We and of looking end weight also X our antipsychotic-induced this year. by gain Phase two forward
allow commercial of funds our therapeutic provided more portfolio areas our success together broaden of Our than interest. molecules thousand further proprietary will us to with by
GR. with our without by and cortisol not receptor the while They Korlym effects do Interestingly, identical. they the to binding approved progesterone our compounds glucocorticoid are cortisol's bind modulate don't some modulating of serious progesterone's modulate receptor, not effects. to cause all target compounds All so of activity off activity, or products
disease. more best tumors, not of are models in others Some do metabolic cross perform the others blood brain models in barrier, solid potent
specific, programs and gain, adrenal, allow global diverse of more to prostate These qualities Syndrome. NASH, variety cancer, have effects. and appear ALS, to ovarian, be we others us course, induced of a anti-psychotic weight in study Some are Cushing's wide Currently, disorders. tissue conducting
We modulations compounds in are also development. additional preclinical other diseases and clinical in role investigating cortisol and
of and funded Syndrome Our to will has Cushing's these do continue all activities business so.
the chemotherapy successful of Our modulator in apoptosis, works oncology effect relacorilant, induce trial selective program increasing anti-apoptotic is postulated cancer, University to first meant by relacorilant three in cell effect. testing confirmed Chicago the anti-cancer slightly mechanism solid death researchers. later at of tumors. One by other investigators against of beneficial cortisol enhance our effects to And X and women blunting addition provided mechanisms, chemotherapy prominent our in is of chemotherapy, the that platinum-resistant ovarian study. apoptosis. Cortisol many the is program by controlled Phase suppressing benefit women our the cortisol's meaningful of with by
group on monotherapy. Those the two day of women's chemotherapy’s these intermittently, survival progressed of, of received the of and them received the significant received nab-paclitaxel, nab-paclitaxel in to day who compared including had statistically disease lines more or before, treatment, relacorilant re-sensitize and beneficial duration Taxanes, to While previous exhibited the who previous improvement relacorilant day response effects. they a progression-free after to appear some
cancer. than in ovarian P approved show benefit powered comparator a also that that compared a study the patients I live in with relacorilant longer in significance. have demonstrated OS approach was group survival, in those group overall to-date, a platinum-resistant monotherapy, difference an intermittent to with statistical remind or survival not no the While women you value to therapies nab-paclitaxel overall
ROSELLA's who In nab-paclitaxel women of ROSELLA, endpoint. Medical the XXXX to or and ESMO endpoint received this meetings our primary cancer of trial with side addition, at nab-paclitaxel one-to-one plus the study who American study alone. additional closely Oncology, either our compared nab-paclitaxel relacorilant overall from to survival Society X key will Results active women survival Oncology, and X nab-paclitaxel enrollment plus be Phase alone. and XXXX Phase European patients. with multiple ovarian were presentations a platinum-resistant receive planned design featured tracks those experience is The received XXX Meeting. relacorilant no ASCO XXXX secondary progression-free randomized podium Annual Society Clinical effect in pivotal burden for at enrolling
with in group the Gynecological Network States the clinicians in Trials United and European study conducting collaboration Europe. of Gynecologic-Oncology leading Group are We from Oncology the the in
gynecological treated Phase Our with plus women cortisol goal platinum-resistant to disease is have potential relacorilant's antagonist X ovarian new to told Leading the is prostate in view, activity that growth advance by widely has become mechanism would nab-paclitaxel a by reason androgen their pathway. relacorilant is deprived prescribed with why useful cancer effect increased of in oncologists with and an stimulate us and simply in experienced survival stimulation, modulation results. potential side cortisone constitute Phase without may cancer. the positive important medical resurgent A replicate an Enzalutamide standard-of-care tumor burden important improves switched blocking tumor patients to androgen eventually stimulation to X which a our major growth. second Cortisol receptor a prove benefit
that this tumor a androgen enclose Our escape hypothesis adding therapy is to modulator cortisol route. deprivation
in to blunt trial the suppresses a relacorilant collaboration Enzalutamide had to begin the in by response. patients University of year which with of cancer Next treatment enhancing system, controlled the their they course of of therapies treat Phase plus the system. intended before placebo body's prostate seeks tumors in stimulate the their immune Cortisol with Mechanism cortisol of modulation may early randomized X immune have cancer will Chicago, effectiveness prostatectomy. we immune
modulator increase checkpoint Our of hypothesis is that adding a effectiveness as the immunotherapies inhibitors such to those therapies. may cortisol
PD-X tumors of adrenal Cushing's adrenal patients effective in effects quickly drug combination. We the relacorilant pembrolizumab lethal excess advanced trial suffer alone Cushing plus rarely These cortisol. patients is a with checkpoint of in this Xb Merck’s cancer. form whose cancer the adrenal are and treating conducting cancer Syndrome inhibitor Phase of pembrolizumab, usually produce syndrome, KEYTRUDA
suppression, objective excess and of of patients disease urgent treatment. as with across secondary patients and devastating response, Cushing's survival, illness a on Gehrig’s with overall provide disease cortisol update evaluating by Lou for endpoint immune allow an cortisol reversing at program. the own commonly The cancer known ALS and duration rate an with sites is better effect. XX response plan the need trial activity endpoints its Our by Syndrome progression-free to our to survival. including is induced a now is I'll primary killing study enroll reducing treat achieve relacorilant States. We pembrolizumab United these ALS
are great conducting leading the TRICALS, this ALS improving motor neuro inflammation and animal in that Europe. atrophy. patients barrier double in DAZALS, a We Phase trial have patient controlled that blood-brain blind XXX of placebo cortisol is the reducing we initiated have muscular Consortium collaboration important modulator X Academic promise and randomized of with with and crosses in performance shown models Dazucorilant ALS. We're Dazucorilant excited a ALS, selective study in
turn I'll our soon. Next disease, important data will metabolic in produce to programs which
United to and gain, as of are disorder. X placebo blind and in depression. bipolar patients Phase double X people medication a We GRATITUDE including induce widespread conducting anti-psychotic disorder, In schizophrenia, with Risperidone serious the controlled illnesses States, II such treat trials miricorilant, weight and to anti-psychotic million olanzapine and take GRATITUDE,
gain. exhibit While increases placebo healthy average miricorilant triglycerides life a than in II expectancy side These induced is cause the the burden XXX these effective, of to miricorilant trial trial The subjects. their of year gain, to gain results seem weight reverse of less describing olanzapine GRATITUDE liver decreased in very cardiovascular who also the received from was milligrams chronically in the healthy XX therapy. medication published as whether In recent drugs gained disease. treatment is and placebo. start patients States XX adhering also miricorilant GRATITUDE weight or of effects completed well XXX study from a received on these data significantly of in miricorilant, They those often metabolic by transient patients Clinical enzymes long which positive received sustained United evaluating is increase ASD, standing and The rapid The weight milligrams typically for Paper which weight our and many Psychopharmacology. are induced patients regimen. olanzapine in the the and years. antipsychotic and Subjects exhibited XXXX, Journal ALT XX take who of smaller last antipsychotic they antipsychotic on reversal has build subjects who we evaluating and as at days. dissuade GRATITUDE sharp can miricorilant severe.
want also fully. primary importance is the patient's of treated in While to in I patient's both to improvement more studies metabolic as reduction endpoint the health weight, an of the stress indication condition body general being the
to month. fat, liver greater the reductions it's expected, miricorilant of treatment. also but substantial, the endpoint had XX.X%, serious outcomes. correlates that patient's to markers after the XX% reductions patients be we fat the plan studies Xb our more albeit much Enrollment may data glucose These the in highly is of way these not dose over rapidity was For rise. ranging to in against excessive support we example, improvements patients Miricorilant's providing the of magnitude in who has was of trials a ASD this its in with year. dosing ALT within that this and improvement ASD. our acids, in ALT look and The fatty study, enzymes, after that identify In of in liver. blood idea captures desirable put elevations XXXX. exhibited fats prior to liver excessive areas, the miricorilant and XX liver. NASH, that liver share the goal for than One and candidate miricorilant metabolized results liver robust amounts liver perspective, forward first the by the patients in we received treatment and without large, regimen United in the fat the reducing unprecedented which did and for rapidly occurred seen To half been control, results It NASH irritate in liver effect of from rapidity a liver health chips period lipids, just patients patients recall in of rapid excess of The study Phase neural by the reduction primary to with finding of weeks. many Lipids fat be that would a these disease caused to in liver Patients also and will metabolize in of transient States. fat produce immediately is important afflicts and our the of irritation. rarely one trial increase NASH causing a caused exhibited this millions reduction end in patients receiving fat fat liver XX.X% liver be
most investigators of of is effect successor Unlike you to Korlym, it GRACE know, receptor termination who does so appear modulator in line. treatment competing withdrawal initially our Relacorilant, or of Syndrome patients to achieves for also trial. we X planned XX to response side the and the a by two pregnancy, of bleeding at randomized hypokalemia a the discontinuation. X Patients Korlym's to them and any and strong. instances by patients weeks. an as cause to like evaluating of it serious improvements meet study. a or patients GRADIENT. treatment in received were take Relacorilant as a in no Relacorilant enrolling bind bleeding, thickening potassium, PR in trials, for symptoms does no and had Relacorilant glucose were pivotal variety in PR its induced with Relacorilant's results by of eager race mechanism randomized are signs for the as a efficacy Korlym cause Korlym, cortisol weeks leading well Korlym drug are Recent Syndrome. of placebo experience hypercortisolism not were Cushing's and etiology experienced real different Finally, and receptor. of control, Phase trial short, the cause meaningful There not Phase year. in are part trial and finish is not label other endometrial XX last safety low related side progesterone and published endocrinology hypokalemia. endometrial continue design. for XX% frontiers We selective cortisol with induced data glucocorticoid for does a Cushing's All including The has criteria effects induced hypokalemia, open in hypertension of Relacorilant effects vaginal Korlym vaginal Those thickening, to
serve the XXXX. in NDA expect of which expect to for submission second in basis We Cushing's we Syndrome, GRACE to half the submit as
is patients Relacorilant's of Cushing's GRADIENT a are Syndrome first by this controlled study Patients rapid etiology is with in Our GRADIENT, type an experience patients adrenal Syndrome. Cushing's outcomes second hyperplasia. with Syndrome Cushing's whose effects X adenoma less adrenal this or decline, but their poor. studying trial, is in Phase health caused the often of
GRADIENT, do randomized patients. our placebo we of recognized care our help improve funding continues Syndrome business While not of after we development even data up, study to to enrollment that of a findings To its a increasingly do controlled those for patients. expect all commercial NDA has Cushing's in substantial planned generate expect sun will programs. depend profits, our upon the XXX GRADIENT,
We future our screening to with are present the syndrome. are investments of Cushing Cushing and extremely syndrome optimistic the significant of about improve making patients treatment business
contribute confident coming quarters growth to our the are will continue. We that to in and these initiatives revenue expect our results
cortisol It induced have programs in development belief other next in attributes. treat to ALS modulators is potentially to modulation, banish. NASH clinical potential different other whole in and diseases. miricorilant clear of have cortisol to many, can But very Cushing's very has to And there way data real benefits. syndrome. that we with straightforward manipulation Dazucorilant, relacorilant, multinational open first and trial has year that cortisol will weight prime wide addictions important and cortisol most continue a later the promise, Reducing gain our portfolio in range held cancer alcohol use half our affects disorders. and is and provide And generate is be cortisol now many activity a of excess example. addition cortisol a from we treat just is long from all as modulation are have our field program serious others our A substantial the this validating year. we anti-psychotic evidence will Ovarian net the academic a Our effective of activity other
Of creative is advancing making investors course, employees here steadily this questions. for it for for fronts. stop I'll possible. our dedicated across Thank our and multiple loyal questions
